<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204666">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000306</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-09262-3</org_study_id>
    <secondary_id>P50-09262-3</secondary_id>
    <nct_id>NCT00000306</nct_id>
  </id_info>
  <brief_title>Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3</brief_title>
  <official_title>Dextroamphetamine as an Adjunct in Cocaine/Opiate Dependent Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an
      adjunct in concurrent cocaine and opiate dependent patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 27-week double-blind, placebo controlled treatment is designed to evaluate
      dextroamphetamine sulfate (sustained release) as an adjunct in concurrent cocaine and opiate
      dependent patients. All subjects will receive methadone. For the treatment of cocaine
      dependence, subjects will receive one of 2 doses of dextroamphetamine (15 or 30mg) or
      placebo. After 4 weeks of treatment the dose level of dextroamphetamine is doubled (30 or
      60mg). This dose is maintained for 20 weeks; during which subjects attend twice weekly
      visits to the clinic and receive weekly cognitive behavioral therapy. Follow up evaluations
      will be conducted out to 3 months post treatment. Subjects will be assisted in transferring
      to Houston area methadone clinics to maintain treatment for opiate dependence following
      treatment completion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1994</start_date>
  <completion_date>September 2001</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Craving</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug use</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication compliance</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Addiction severity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Mood indicators</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Psychiatric interview</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness measures including psycho-social variables, side effects, and self-reported measures.</measure>
  </secondary_outcome>
  <enrollment>140</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <condition>Opioid-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextroamphetamine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria- Subject must:

          -  Exhibit cocaine and opiate dependence through a DSM-IV diagnosis as determined by
             SCID.

          -  Be between 18 and 45 years old

          -  Women must agree to use contraception

          -  Have an EKG that has been confirmed by a cardiologist

          -  Give a cocaine positive urine during screening - Present with evidence of opiate
             withdrawal

        Exclusion Criteria- Subject must not:

        â€¢ Have a serious medical illness including, but not limited to the following: Hypertension
        Significant heart disease Clinically significant cardiovascular abnormality Angina
        Hepatic, renal, or gastrointestinal disorders that could result in an altered metabolism
        or excretion of study agent

          -  Have any Axis I disorder that is not related to drug use

          -  Have current dependence on any psychoactive disorder other than nicotine

          -  Be on probation or parole for reasons other than those related to drug charges (ASI)

          -  Be pregnant or lactating

          -  Have been in any outside treatment in 3 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Grabowski, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <lastchanged_date>August 11, 2008</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
